Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 4Unknown 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 6Colorectal Neoplasms 4Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Inflammatory Breast Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 2Taxes 2Carboplatin 2Panitumumab 1Paclitaxel 1Neoadjuvant Therapy 1Doxorubicin 1Cyclophosphamide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Inflammatory Breast Neoplasms × Neoadjuvant Therapy × Clear all
NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Medstar Health Research Institute

Phase 2/3 Withdrawn
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡